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Overview
• Review historical perspective and complexity of primary CVD 
prevention
• Discuss primary & secondary prevention of CAD and the 2019 
ACC/AHA guidelines 
• Review of the evidence & primary literature
• Focus on CV risk assessment, DM, ASA/DAPT
• Practical guidance and management considerations
• CASES- let’s practice and discuss
What we will not be talking about:
• Diagnosis and Management of acute coronary syndromes or ischemic 
heart disease
• Cardiac imaging modalities for CAD stress tests, other imaging 
modalities
• Cardiac catheterization, CABG and Revascularization procedures
CAD Prevention and Historical Context
Previous studies suggested as much has 50% patients with CHD had no 
identifiable risk factors
Greenland et al(2003): 3 prospective cohort studies:
• Chicago Heart Association Detection Project (35 642 M/W 18-59)
• Multiple Risk Factor Intervention Trial (347 978 M 35-57)
• Framingham Heart Study (3295 M/W 34-59)
Main Outcomes: Fatal CHD nonfatal MI preceded by major CHD risk 
factors (TC >240, SBP> 140, DBP >90 mm Hg cigarette smoking, and 
diabetes)
Findings: For fatal CHD (n = 20 995) 87-100% had 1+ RF (87-94% 40-59y) 
Non fatal MI 92% men, 87% of women
2010 AHA Model for Ideal CV Health
2019 ACC/AHA Guidelines on the Primary Prevention of 
Cardiovascular disease 
Top 10 Take-Home Messages
•2019 Primary 
Prevention 
Guidelines
Top 10 Take Home Messages
1. The most important way to prevent 
atherosclerotic vascular disease, heart 
failure, and atrial fibrillation is to promote a 
healthy lifestyle throughout life. 
How?
Top 10 Take home messages
2. A team-based care approach is an effective 
strategy for the prevention of cardiovascular 
disease. Clinicians should evaluate the 
social determinants of health that affect 
individuals to inform treatment decisions.
This includes emphasis on shared decision-making w/ patient and family
CMS 
Screening 
Tool
3. Adults who are 40 to 75 years of age and are being 
evaluated for cardiovascular disease prevention should 
undergo 10-year atherosclerotic cardiovascular disease 
(ASCVD) risk estimation and have a clinician–patient risk 
discussion before starting on pharmacological therapy, 
such as antihypertensive therapy, a statin, or aspirin. In 
addition, assessing for other risk-enhancing factors can 
help guide decisions about preventive interventions in 
select individuals, as can coronary artery calcium 
scanning.
Top 10 Take Home Messages
Assessment of Cardiovascular Risk
Recommendations for Assessment of Cardiovascular Risk
COR LOE Recommendations
I B-NR
1. For adults 40 to 75 years of age, clinicians should routinely assess
traditional cardiovascular risk factors and calculate 10-year risk of ASCVD
by using the pooled cohort equations (PCE).
IIa B-NR
2. For adults 20 to 39 years of age, it is reasonable to assess traditional
ASCVD risk factors at least every 4 to 6 years.
IIa B-NR
3. In adults at borderline risk (5% to <7.5% 10-year ASCVD risk) or
intermediate risk (≥7.5% to <20% 10-year ASCVD risk), it is reasonable to
use additional risk-enhancing factors to guide decisions about preventive
interventions (e.g., statin therapy).
Assessment of Cardiovascular Risk (cont’d)
Recommendations for Assessment of Cardiovascular Risk
COR LOE Recommendations
IIa B-NR
4. In adults at intermediate risk (≥7.5% to <20% 10-year ASCVD risk) or
selected adults at borderline risk (5% to <7.5% 10-year ASCVD risk), if risk-
based decisions for preventive interventions (e.g., statin therapy) remain
uncertain, it is reasonable to measure a coronary artery calcium score to
guide clinician–patient risk discussion.
IIb B-NR
5. For adults 20 to 39 years of age and for those 40 to 59 years of age who
have <7.5% 10-year ASCVD risk, estimating lifetime or 30-year ASCVD risk
may be considered.
Risk Calculator 40-75yrs old
CV Risk assessment in younger Adults:
Largely based on Framingham data and 30 year/lifetime risk estimates
Risk-Enhancing Factors
• Family history of premature ASCVD (males, age <55 y; females, age <65 y)
• Primary hypercholesterolemia (LDL-C 160–189 mg/dL [4.1–4.8 mmol/L]; non–HDL-C 190–219 mg/dL 
[4.9–5.6 mmol/L])*
• Metabolic syndrome (increased waist circumference [by ethnically appropriate cutpoints], elevated 
triglycerides [>150 mg/dL, nonfasting], elevated blood pressure, elevated glucose, and low HDL-C [<40 
mg/dL in men; <50 mg/dL in women] are factors; a tally of 3 makes the diagnosis)
• Chronic kidney disease (eGFR 15–59 mL/min/1.73 m2 with or without albuminuria; not treated with 
dialysis or kidney transplantation)
• Chronic inflammatory conditions, such as psoriasis, RA, lupus, or HIV/AIDS
Risk-Enhancing Factors
• History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that 
increase later ASCVD risk, such as preeclampsia
• High-risk race/ethnicity (e.g., South Asian ancestry)
• Lipids/biomarkers: associated with increased ASCVD risk
• Persistently elevated,* primary hypertriglyceridemia (≥175 mg/dL, nonfasting);
• If measured:
§ Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)
§ Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An 
Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor, especially at higher levels of 
Lp(a).
§ Elevated apoB (≥130 mg/dL): A relative indication for its measurement would be triglyceride ≥200 
mg/dL. A level ≥130 mg/dL corresponds to an LDL-C >160 mg/dL and constitutes a risk-enhancing 
factor
§ ABI (<0.9)
High- Sensitivity CRP and CAD
• Elevated CRP has been associated 
with increased risk for CVD
• Independent of additional RFs
• Benefit in addition to traditional 
CV risk estimates appears small
• Reclassifies risk in about 1.5%
• 1 CV event/10 yrs per 400-500 
screened
• Benefit appears highest in those 
with intermediate (10-20% 10yr 
risk)
Who should I screen?:
Consider for those at intermediate 
risk for whom it may impact 
treatment decisions
What levels are abnormal?
<1mg/L = low risk
>2-3mg/L = higher risk
Lipoprotein a (Lp(a)) and CAD
Lp(a) and CAD
• Statin (+/- ezetimibe) therapy 
not effective in lowering Lp(a)-
and may increase
• PCSK9 Ab’s have been 
associated w/ 25% reduction in 
Lp(a) and reductions mortality 
and risk for MI
• Limited by costs- consider 
stratifying use to those with high 
Lp(a) and LDL above goal
Lp(a) and CAD- Who to Test?
• No clear consensus but elevated Lp(a) clearly associated w/ 
CAD risk
• Consider in non-diabetics 40-75yr at intermediate risk (to start 
statin)
• Those with primary LDL>190—inc’d risk of Lp(a) excess or 
premature ASCVD
• Those who cannot reach LDL goals with appropriate intensity 
statin (+/- ezetimibe) to consider PCSK9Ab
Apolipoprotein B (ApoB) and CAD
• Apo B is the major apolipoprotein
in LDL+VLDL. 
• Non-HDL is used as a surrogate 
• Some studies have suggested 
ApoB is a more potent marker of 
CVD risk than LDL or non-HDL
• Others have shown non-HDL and 
ApoB levels are highly corelated
• Less so with HyperTG
• When to consider ApoB:
• To assess risk for ASCVD for 
patients with persistent 
hypertriglyceridemia (>200 
mg/dL)despite statin +/- fibrate 
therapy
ABI and PAD screening in Cardiovascular Disease
• A 2005 meta-analysis of 9 studies found ABI <0.9 is specific 
(92%)  but not sensitive (16%) for predicting incident 
cardiovascular disease (LR 2.53%), CV death (LR 5.6)
• Better for ruling in than ruling out CVD
• Presence of PAD is ASCVD equivalent and would warrant 
treatment as such
Coronary Artery Calcium Scoring
Adding CAC to traditional CV risk 
calculators yielded risk estimates 8-9% 
higher for those participants who had CV 
events vs non-events
Calculator
Table 6. Selected Examples of Candidates for CAC Measurement 
Who Might Benefit from Knowing Their CAC Score is Zero
CAC Measurement Candidates Who Might Benefit from Knowing Their CAC 
Score Is Zero
• Patients reluctant to initiate statin who wish to understand their risk and 
potential for benefit more precisely
• Patients concerned about need to reinstitute statin therapy after 
discontinuation for statin-associated symptoms
• Older patients (men 55–80 y of age; women 60–80 y of age) with low 
burden of risk factors (S4.4-42) who question whether they would benefit 
from statin therapy
• Middle-aged adults (40–55 y of age) with PCE-calculated 10-year risk for 
ASCVD 5% to <7.5% with factors that increase their ASCVD risk, although 
they are in a borderline risk group.
CAC and CV risk: Take home Points
• Consider in adults at intermediate 
risk (≥7.5-<20% 10-year ASCVD) or 
selected adults at borderline risk (5-
<7.5% 10-year ASCVD)
• CAC < 1 is highly predictive of low 10 
yr. CV risk (most useful in ruling out 
significant CAD risk)
• CAC >100 is predictive of at least 
intermediate risk
• Limitations:
• Not covered my most insurance 
companies ($100-400)
• Radiation risk
Take home points:
• For patients at intermediate ASCVD risk consider:
• Advanced biomarker testing --Hs-CRP, Lp(a) (best data), apoB
• ABI
• Coronary Artery calcium scoring
… After assessing for risk enhancing conditions IF it will change 
management/risk classification
4. All adults should consume a healthy diet that 
emphasizes the intake of vegetables, fruits, nuts, 
whole grains, lean vegetable or animal protein, and 
fish and minimizes the intake of trans fats, red meat 
and processed red meats, refined carbohydrates, and 
sweetened beverages. For adults with overweight and 
obesity, counseling and caloric restriction are 
recommended for achieving and maintaining weight 
loss.
Top 10 Take Home Messages
5. Adults should engage in at least 150 minutes 
per week of accumulated moderate-
intensity physical activity or 75 minutes per 
week of vigorous-intensity physical activity.                                         
Top 10 Take Home Messages
Americans and Exercise: 
Intensity METs Examples
Sedentary
behavior*
1–1.5 Sitting, reclining, or lying;
watching television
Light 1.6–2.9 Walking slowly, cooking, light
housework
Moderate 3.0 –5.9 Brisk walking (2.4–4 mph),
biking (5–9 mph), ballroom
dancing, active yoga,
recreational swimming
Vigorous ≥6 Jogging/running, biking (≥10
mph), singles tennis,
swimming laps
6. For adults with type 2 diabetes mellitus, 
lifestyle changes, such as improving dietary 
habits and achieving exercise 
recommendations, are crucial. If medication 
is indicated, metformin is first-line therapy, 
followed by consideration of a sodium-
glucose cotransporter 2 inhibitor or a 
glucagon-like peptide-1 receptor agonist. 
Top 10 Take Home Messages
Fig. 2. Treatment of T2DM for Primary Prevention of CVD
Metformin and CVD Risk Reduction
Metformin and CVD Risk Reduction
• 2017 Meta-analysis of 13 RCTs 
Metformin vs Placebo:
• All outcomes, with the exception 
of stroke, favored metformin. 
None significant
• Effect sizes:
• All-cause mortality 0.96 (95% CI 
0.84, 1.09)
CV Death 0.97 (95% CI 0.80, 1.16)
MI 0.89 (95% CI 0.75, 1.06)
Stroke 1.04 (95% CI 0.73, 1.48)
PVD 0.81 (95% CI 0.50, 1.31)
SGLT-2 Inhibitors and CVD Risk Reduction
GLP-1 Agonists and CVD Risk Reduction
• Significant reductions to 3 point 
MACE, CV mortality and all cause
• No overall inc. in Aes
• Limitations:
• Only patients w/ known CAD 
included in trials
• No clear evidence of fatal and 
non-fatal MI reduction
Comparison of DM drug classes in CV Disease Outcomes
7. All adults should be assessed at every 
healthcare visit for tobacco use, and those 
who use tobacco should be assisted and 
strongly advised to quit.  
Top 10 Take Home Messages
8. Aspirin should be used infrequently in the 
routine primary prevention of ASCVD because 
of lack of net benefit.
Top 10 Take Home Messages
Aspirin Use
Recommendations for Aspirin Use
COR LOE Recommendations
IIb A
1. Low-dose aspirin (75-100 mg orally daily) might be considered for the
primary prevention of ASCVD among select adults 40 to 70 years of age
who are at higher ASCVD risk but not at increased bleeding risk.
III: 
Harm B-R
2. Low-dose aspirin (75-100 mg orally daily) should not be administered on
a routine basis for the primary prevention of ASCVD among adults >70
years of age.
III: 
Harm C-LD
3. Low-dose aspirin (75-100 mg orally daily) should not be administered
for the primary prevention of ASCVD among adults of any age who are
at increased risk of bleeding.
ASA for Primary Prevention of CAD
• ASCEND:  RCT of 15,480 patients 
with DM, no known CAD  (mean 
f/u 7.4 years)
• Most pts on statin(75%), HTN Tx
• 12% lower risk for CV events
• 29% higher major bleeding risk
ASA for Primary Prevention of CAD
• Based on this data USPSTF made 
grade B rec for adults 50-59 w/ 
>10%  10yr ASCVD risk (C for 60-
69 and I for <50 or >70yo)
• ASA has failed to show robust 
benefit across multiple study 
groups for primary prevention 
(low ABI, DM)
22% dec in non-fatal MI, 6% all cause
ASA for Primary Prevention of CAD
• Despite reducing evidence of 
benefits NNT to prevent ASCVD 
event > NNH via bleeding event
• Consider ASA If:  No factors 
increasing bleeding risk, ASCVD 
risk >10% and/or patient is 
unable to control other ASCVD 
risk factors- shared decision 
making with patient
How Do we Assess Bleeding Risk?
• Hx of previous GI bleed/PUD 
• Hx of ICH/other significant bleed
• age >70 years, 
• Thrombocytopenia
• coagulopathy 
• CKD
• Concurrent use of:
• NSAIDS, Steroids, DOACs/warfarin, 
SSRI
• http://www.asariskcalculator.com/
• http://www.aspiringuide.com
9. Statin therapy is first-line treatment for 
primary prevention of ASCVD in patients 
with elevated low-density lipoprotein 
cholesterol levels (≥190 mg/dL), those with 
diabetes mellitus, who are 40 to 75 years of 
age, and those determined to be at 
sufficient ASCVD risk after a clinician–
patient risk discussion.
Top 10 Take Home Messages

10.Nonpharmacological interventions are 
recommended for all adults with elevated 
blood pressure or hypertension. For those 
requiring pharmacological therapy, the 
target blood pressure should generally be 
<130/80 mm Hg.
Top 10 Take Home Messages
Figure 4. BP Thresholds and Recommendations for Treatment
BP indicates blood pressure; and CVD, cardiovascular disease.
Table 7. Best Proven Nonpharmacological Interventions For 
the Prevention and Treatment of Hypertension
Nonpharmacological 
Intervention
Goal Approximate Impact on SBP
Hypertension Normotension Reference
Weight loss Weight/body fat Best goal is ideal body 
weight, but aim for at least 
a 1-kg reduction in body 
weight for most adults who 
are overweight. Expect 
about 1 mm Hg for every 1-
kg reduction in body 
weight.
-5 mm Hg -2/3 mm Hg (S4.4-2)
Healthy diet DASH dietary pattern‡ Consume a diet rich in 
fruits, vegetables, whole 
grains, and low-fat dairy 
products, with reduced 
content of saturated and 
total fat.
-11 mm Hg -3 mm Hg (S4.4-7, S4.4-8)
Reduced intake 
of dietary sodium
Dietary sodium Optimal goal is <1500 
mg/d, but aim for at least a 
1000-mg/d reduction in 
most adults.
-5/6 mm Hg -2/3 mm Hg (S4.4-12, S4.4-10)
Enhanced intake 
of dietary 
potassium
Dietary potassium Aim for 3500–5000 mg/d, 
preferably by consumption 
of a diet rich in potassium.
-4/5 mm Hg -2 mm Hg (S4.4-14)
Table 7. Best Proven Nonpharmacological Interventions For 
the Prevention and Treatment of Hypertension (cont’d)
Nonpharmacological 
Intervention
Goal Approximate Impact on SBP
Hypertension Normotension Reference
Physical activity Aerobic • 90–150 min/wk
• 65%–75% heart rate 
reserve
-5/8 mm Hg -2/4 mm Hg (S4.4-19, S4.4-20)
Dynamic resistance • 90–150 min/wk
• 50%–80% 1 rep 
maximum
• 6 exercises, 3 
sets/exercise, 10 
repetitions/set
-4 mm Hg -2 mm Hg (S4.4-19)
Isometric resistance • 4 × 2 min (hand 
grip), 1 min rest 
between exercises, 
30%–40% maximum 
voluntary 
contraction, 3 
sessions/wk
• 8–10 wk
-5 mm Hg -4 mm Hg (S4.4-21, S4.4-63)
Moderation in 
alcohol intake
Alcohol consumption In individuals who drink 
alcohol, reduce alcohol† to:
• Men: ≤2 drinks daily
• Women: ≤1 drink 
daily
-4 mm Hg -3 mm Hg (S4.4-20, S4.4-24, 
S4.4-25)
What’s the data for intensive BP control?
Take home points re: Treatment goals
• BP target <130/80 w/ pharmacotherapy if:
• 10 year ASCVD risk >10%
• CKD
• DM2
• Data suggests this may contribute to reduction in major CV 
events and MI but overall mortality benefit unclear
2019 ACC/AHA Guidelines on the Primary Prevention of 
Cardiovascular disease 
Clinic Evaluation of Patients with Stable CAD (SIHD)
• At least Annual Follow up:
• a. Assessment of symptoms and clinical function;
• b. Surveillance for complications: heart failure and arrhythmias
• c. Monitor risk factors: re-assess lifestyle & medical therapy
• IF evidence of MI or worsening HF: asses LVEF and segmental 
wall motion by echocardiography or radionuclide imaging
• Consider resting 12-lead ECG at 1-year or longer if symptoms 
stable
• No evidence for routine echo in stable patients with normal EF
Secondary Prevention : Guidelines Directed Medical 
Therapy
• Lifestyle modifications 
• Physical activity, weight mgmt, dietary mod, tobacco cessation, 
ETOH moderation
• Lipid management as per 2018 AHA/ACC guidelines (high-or 
moderate-intensity statin)
• HTN management: Goal BP <130/80 (especially if DM or CKD) 
• include ACEi (or ARB) and/or beta blockers.  Other meds as need to 
achieve BP goal.  
• Optimize diabetic control A1c<7% (metformin+ GLP1 or SGLT2i)
• Antiplatelet therapy- ASA 81mg (A,Clopidogrel (B) if contraind.)
Secondary Prevention : Guideline Directed Medical 
Therapy (Goal: prevent second event)
• HTN management: Goal BP <130/80 (especially if DM or CKD)
• BP targets somewhat controversial  
• ACEi/ARB (Hx of MI, CHF/LV dysf/CKD, DM)
• Beta blocker: Hx of MI, angina, LV dysfunction
• Adjuncts:
• Aldosterone antagonist if LV dysf (<40%EF)
• Calcium channel blocker if angina
• Optimize diabetic control A1c<7% (B) (SDM older patients)
• metformin+ GLP1 or SGLT2i (Avoid Thiazolidinediones)
Comparison of DM drug classes in CV Disease Outcomes
Use of Beta Blockers to Prevent MI, CV death:
• Beta-blocker:
• 3 years in all patients with normal LV function after MI or 
ACS(IB)
• all patients with LV systolic dysfunction (EF ≤40%) with heart 
failure or prior MI
• carvedilol, metoprolol succinate, or bisoprolol: demonstrated 
mortality benefit (IA)
• Consider for all other patients with CAD
DAPT: Dual Antiplatelet Therapy
• No indication unless recent MI, 
PCI, CABG
• All patients with CAD s/p ACS
• 12 mo DAPT (regardless of 
intervention)
• SIHD requiring intervention: 
• BMS: >1mo
• DES >6 mo
• CABG: 12 mo (less clear data)
• Consider longer duration if 
thrombotic risk>bleeding risk
Duration of DAPT: Ischemia vs Bleeding Risk
*Consider PPI for those at inc. bleeding 
risk (I-Hx GIB, IIa-other inc risk)
Cardiac Rehabilitation
• When to Refer:
• Recent ACS s/p CABG or PCI @ hospital 
d/c or TOC(IA)
• Dx in last 1 yr:
• ACS s/p CABG or PCI (IA)
• chronic angina (IB)
• PAD (IA)
• Clinically stable outpatients with 
diagnosis of heart failure (IIa/B)
• Can substitute home based cardiac 
rehab program for low risk patients (IA)
• Meta-analysis of 48 RCTs of exercise 
interventions (med duration 3mo):
• 20% reduction in all-cause mortality
• 26% reduction in CV mortality 
• Non-sig but fav. Trends:
• nonfatal MI, CABG, PCI 
• No difference between the mortality 
rate effects of exercise-only and 
more comprehensive cardiac 
rehabilitation interventions, and the 
benefits were independent of actual 
amount and intensity of exercise.
Pharmacotherapy for Chronic Anginal Sx:
• 1st line: Beta blockers (IB)
• 2nd line: Calcium channel blockers or long-acting nitrates (IB) 
–if unable to tolerate BB
• Add: Calcium channel blockers or long-acting nitrates if 
persistent sx on BB
• Sublingual nitroglycerin or nitroglycerin spray is 
recommended for immediate relief
Checklist for your patients with CAD:
ü ASA therapy?
ü Indication for DAPT?
ü ACS/PCI/CABG in last 12 mo
ü Beta blocker?
ü ACEi/ARB?
ü High intensity statin?
ü Diabetic control?
ü If A1c >7 consider GLP1, SGLT-2
ü Tobacco cessation?
ü ETOH moderation/cessation
ü Depression/socioeconomic 
screening
ü Physical activity/weight mgmt 
ü Eval chronic angina?
ü BB, CCB or nitrate
ü Assess for interval MI, sx of 
worsening HF
Coronary Artery Disease: CASES 
in Primary Prevention
Case 1
• 55yo Male with PMH HTN, DM, 
remote PUD, tobacco use 
presents for a NPV TOC visit after 
recent stay in OSH with a recent 
STEMI of LAD managed with PCI 
and DES stent.  Echocardiogram 
prior to discharge showed EF of 
35%.
• Labs:  A1c 8.8%, LDL 186, TG 255, 
HDL 30, Cr 1.2
VS:  HR 82, BP 150/92, BMI 43
• His current meds are:
ASA 81mg, Clopidogrel 75mg daily, 
Metformin 1000mg BID, Lisinopril
40mg, Atorvastatin 40mg, 
Furosemide 20mg daily
1. How would you counsel this 
patient?
2. What management recs would you 
make?
Case 2
• 52yo AAF Female presents to your 
office to establish care. Her PMH is 
significant for HTN, Depression and 
HIV. Her BP is 130/76.  BMI 32
• Her meds are as follows:  
Chlorthalidone 25mg, 
Darunavir/ritonavir + Descovy
(TAF/Emtricitabine), Sertraline
100mg
• She is a non-smoker
• She is reluctant to change any meds
• Labs:
• Tot Chol: 205
• HDL 35
• LDL 126
• A1c: 6.0%
• Cr 1.4 (CrCl 49)
• VL <40, CD4 450
• Assess her ASCVD 10yr risk
• Discuss any medication changes or 
additional testing.
Case 3
• 56yoM w/ PMH severe Hip OA DM2, CAD s/p NSTEMI w/ PCI 
and DES 3 months ago comes to you for pre-operative 
evaluation an clearance.  He has completed cardiac rehab 
program and is symptom free on the following meds:
• ASA 81mg, Atorvastatin 40mg, metoprolol XL 50mg daily, Lisinopril 20mg daily, 
clopidogrel 75mg daily, metformin 1000mg BID, lantus 20 units daily
1. Any other information to you want to know?
2.Would you make any changes to his medication regimen?
3. How would you counsel him regarding his procedure?  
Perioperative management & DAPT in CAD
Case 4
• 47yo Caucasian Male presents to your office to review his 
biometric screening results:  
• TC: 250, HDL 30, LDL 170, TG 250, A1c 5.8%, BP 138/86
• He is a non-smoker, his BMI is 36, and he has been taking ASA 
81 mg for the last 6 mo after his brother died at 54 from MI
• He wants to do EVERYTHING to reduce his CV risk.  How 
would you counsel him?  Additional testing? Meds?
Case 5
• 75yo AA Female who present for routine follow up.  She has a 
remote hx of MI treated with PCA in her 50s, HTN, DM, CKD, 
GERD. She is a former smoker and quit 15 yrs ago.  Echo last 
year showed EF 45%. Her BP is 140/86 on exam.
• Labs: A1c: 8%, LDL 66, HDL 40, Tot Chol: 180, Cr 1.4 (CrCl 40)
• Meds: ASA 81mg, Atorvastatin 80mg, Metformin 100mg BID, 
Metoprolol 50mg, lisinopril 20mg, Omeprazole 40mg
• Would you make any changes to he regimen? Considerations?
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